Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire - Thu Dec 4, 6:30AM CST

CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.3598 (+4.41%)
NRSN : 0.9900 (-15.38%)
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PR Newswire - Mon Nov 24, 8:56AM CST

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSN : 0.9900 (-15.38%)
NeuroSense to Host Investor Webinar on December 8, 2025 PR Newswire - Mon Nov 3, 8:15AM CST

Business, regulatory and clinical updates will be provided

NRSNW : 0.3598 (+4.41%)
NRSN : 0.9900 (-15.38%)
Neurosense Therapeutics Ltd. (NRSN) Receives a New Rating from Noble Financial Tipranks - Fri Oct 17, 6:10AM CDT

Neurosense Therapeutics Ltd. received a Buy rating and a $9.00 price target from Noble Financial analyst Robert LeBoyer on October 14. The company’s shares closed yesterday at $1.24.Elevate Your Investing...

NRSN : 0.9900 (-15.38%)
NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC Tipranks - Tue Oct 7, 8:32AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Neurosense...

NRSN : 0.9900 (-15.38%)
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers PR Newswire - Mon Oct 6, 8:00AM CDT

CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSN : 0.9900 (-15.38%)
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons PR Newswire - Wed Sep 10, 1:30PM CDT

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile

NRSN : 0.9900 (-15.38%)
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price PR Newswire - Thu Sep 4, 7:49AM CDT

Financing at 40% premium to market price provides near-term bridge to anticipated milestones

NRSN : 0.9900 (-15.38%)
NeuroSense Provides Business Update and Progress for the First Half of 2025 PR Newswire - Fri Aug 1, 8:00AM CDT

CAMBRIDGE, Mass. , July 31, 2025 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments...

NRSN : 0.9900 (-15.38%)
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community PR Newswire - Tue Jul 22, 7:42AM CDT

Live Broadcast: Award-Winning Actor & ALS Advocate Aaron Lazar hosts NeuroSense CEO Alon Ben-Noon to Unveil New Insights into NeuroSense's Breakthrough Science, Canadian Regulatory Milestones &...

NRSN : 0.9900 (-15.38%)

Barchart Exclusives

After a Red-Hot Rally on S&P 500 Inclusion, Carvana Stock Needs a ‘Cool’ Option Collar. How to Trade CVNA Here. Barchart - 34 minutes ago
Here’s how you can keep chasing the upside in Carvana while minimizing your downside risk. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot